Dimensional Fund Advisors LP Has $16.82 Million Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Dimensional Fund Advisors LP boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 1,565.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 269,825 shares of the company's stock after buying an additional 253,624 shares during the period. Dimensional Fund Advisors LP owned approximately 0.80% of TransMedics Group worth $16,820,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of TMDX. Wilmington Savings Fund Society FSB bought a new position in TransMedics Group during the third quarter worth $149,000. Principal Financial Group Inc. increased its holdings in shares of TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock worth $31,759,000 after purchasing an additional 146,115 shares during the period. Fiduciary Alliance LLC acquired a new position in shares of TransMedics Group during the fourth quarter valued at about $247,000. Talbot Financial LLC acquired a new position in shares of TransMedics Group during the fourth quarter valued at about $300,000. Finally, Harbour Capital Advisors LLC lifted its stake in shares of TransMedics Group by 33.3% in the fourth quarter. Harbour Capital Advisors LLC now owns 6,452 shares of the company's stock valued at $446,000 after buying an additional 1,611 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMDX has been the topic of several research reports. Oppenheimer boosted their price target on TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Finally, Piper Sandler restated an "overweight" rating and set a $125.00 target price (up previously from $105.00) on shares of TransMedics Group in a research note on Friday. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $126.70.

TransMedics Group Price Performance

TransMedics Group stock traded up $18.30 during mid-day trading on Friday, reaching $111.50. The company had a trading volume of 4,541,391 shares, compared to its average volume of 1,348,071. The business has a fifty day simple moving average of $78.53 and a 200 day simple moving average of $75.42. The company has a market cap of $3.77 billion, a P/E ratio of 118.62 and a beta of 1.91. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's revenue for the quarter was up 48.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.35 EPS. On average, equities research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.